National Institutes of Health

Description

This Funding Opportunity Announcement (FOA) solicits applications for projects to develop strategies to target the human pancreatic environment in-vivo to deliver cell-based therapeutics, regulatory molecules or gene constructs that can protect or replenish the functional beta cell mass, or to develop synthetic sentinel biomarkers to safely monitor beta cell stress or disease initiation prior to the appearance of autoantibodies in individuals at risk of developing Type 1 Diabetes (T1D). Successful applicants will join the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase functional human beta cell mass in vivo through the controlled manipulation of beta cell replication, islet cell plasticity, or the reprogramming of pancreatic non-beta cells into beta-like cells. CTAR is part of the Human Islet Research Network (HIRN).

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV